The 2021 SVF hair-loss study and how it fits with existing medication
Quick answer
The SVF scalp programme injects autologous adipose cells into the scalp to improve perifollicular circulation, reduce inflammation and extend the growth phase. The centre's medical director published SVF hair-loss research in Stem Cell Research & Therapy in 2021. Responders are typically early-to-moderate thinning with follicles still present — not fully bald areas.
Follicles need steady perfusion to stay in anagen. In pattern hair loss the perifollicular capillary bed shrinks and low-grade inflammation sets in, so delivering cells that secrete angiogenic factors targets the follicular environment rather than replacing dead follicles.
The sensible plan treats cell therapy as an add-on, not a substitute for proven drugs. Men on finasteride or minoxidil should not stop them to 'test' the cells: stopping typically loses maintained hair within months and makes the cell effect impossible to judge.
Measure with methods you can audit: fixed-point photography at the same distance and lighting every three months, plus trichoscopy for hairs per square centimetre and the proportion of miniaturised hairs. Those numbers beat the impression of 'less shedding'.
Thai patients travelling to Korea should ask in advance how many sessions the programme includes, whether repeat visits are expected, and what maintenance can be continued at home — long-term outcome depends on follow-through as much as on the procedure.
Not where follicles are gone. Cell therapy supports surviving follicles; truly bald areas still require transplantation.
Yes, but screen for contributors first — low ferritin, thyroid disease or hormonal issues — since correcting the cause usually yields more than any procedure.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Body recovery & aging